Working… Menu

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03054363
Recruitment Status : Recruiting
First Posted : February 15, 2017
Last Update Posted : July 26, 2019
University of Colorado, Denver
Information provided by (Responsible Party):
University of Colorado, Denver ( Academic Thoracic Oncology Medical Investigators Consortium )

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 31, 2019
Estimated Study Completion Date : October 31, 2020